These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30666285)

  • 1. The importance and implications of comparator selection in pharmacoepidemiologic research.
    D'Arcy M; Stürmer T; Lund JL
    Curr Epidemiol Rep; 2018 Sep; 5(3):272-283. PubMed ID: 30666285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.
    Lund JL; Richardson DB; Stürmer T
    Curr Epidemiol Rep; 2015 Dec; 2(4):221-228. PubMed ID: 26954351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators.
    Huitfeldt A; Hernan MA; Kalager M; Robins JM
    EGEMS (Wash DC); 2016; 4(1):1234. PubMed ID: 27891526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations.
    Kim DH; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):891-901. PubMed ID: 24962929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research.
    Secrest MH; Platt RW; Dormuth CR; Chateau D; Targownik L; Nie R; Doyle CM; Dell'Aniello S; Filion KB
    Pharmacoepidemiol Drug Saf; 2020 Jan; 29 Suppl 1():26-34. PubMed ID: 30628152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies.
    Acton EK; Willis AW; Hennessy S
    Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):9-18. PubMed ID: 36216785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators.
    Sendor R; Stürmer T
    Pharmacoepidemiol Drug Saf; 2022 Mar; 31(3):261-269. PubMed ID: 35019190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review.
    Prada-Ramallal G; Takkouche B; Figueiras A
    BMC Med Res Methodol; 2019 Mar; 19(1):53. PubMed ID: 30871502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of Comparator Group in Observational Drug Safety Studies: Alternatives to the Active Comparator New User Design.
    Wintzell V; Svanström H; Pasternak B
    Epidemiology; 2022 Sep; 33(5):707-714. PubMed ID: 35944152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of how missing data are handled and reported in multi-database pharmacoepidemiologic studies.
    Hunt NB; Gardarsdottir H; Bazelier MT; Klungel OH; Pajouheshnia R
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):819-826. PubMed ID: 33834576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions for the management of obesity in people with bipolar disorder.
    Tully A; Smyth S; Conway Y; Geddes J; Devane D; Kelly JP; Jordan F
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013006. PubMed ID: 32687629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invited Commentary: The Prevalent New-User Design in Pharmacoepidemiology-Challenges and Opportunities.
    Filion KB; Yu YH
    Am J Epidemiol; 2021 Jul; 190(7):1349-1352. PubMed ID: 33350439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of disease-risk score in pharmacoepidemiologic studies].
    Zhao HY; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):261-266. PubMed ID: 28231678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active-comparator design and new-user design in observational studies.
    Yoshida K; Solomon DH; Kim SC
    Nat Rev Rheumatol; 2015 Jul; 11(7):437-41. PubMed ID: 25800216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs.
    Etminan M; Samii A
    Pharmacotherapy; 2004 Aug; 24(8):964-9. PubMed ID: 15338844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations on the use of different comparators in pharmacovigilance: A methodological review.
    Gravel CA; Douros A
    Br J Clin Pharmacol; 2023 Sep; 89(9):2671-2676. PubMed ID: 37226576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restriction of Pharmacoepidemiologic Cohorts to Initiators of Medications in Unrelated Preventive Drug Classes to Reduce Confounding by Frailty in Older Adults.
    Zhang HT; McGrath LJ; Ellis AR; Wyss R; Lund JL; Stürmer T
    Am J Epidemiol; 2019 Jul; 188(7):1371-1382. PubMed ID: 30927359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research.
    Schneeweiss S; Stürmer T; Maclure M
    Pharmacoepidemiol Drug Saf; 1997 Oct; 6 Suppl 3():S51-9. PubMed ID: 15073755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.